Real-world effectiveness of systemic anticancer therapy for advanced melanoma in the west of Scotland from 2010 to 2018

Clarke, Julie and Bennie, Marion and Kurdi, Amanj and Pan, Jiafeng and Mueller, Tanja and Crearie, Christine and Baillie, Kelly and Laskey, Jennifer and Waterston, Ashita (2023) Real-world effectiveness of systemic anticancer therapy for advanced melanoma in the west of Scotland from 2010 to 2018. Future Oncology, 19 (6). pp. 451-461. ISSN 1479-6694 (https://doi.org/10.2217/fon-2022-0959)

[thumbnail of Clarke-etal-FO-2023-Real-world-effectiveness-of-systemic-anticancer-therapy-for-advanced-melanoma]
Preview
 Text. Filename: Clarke_etal_FO_2023_Real_world_effectiveness_of_systemic_anticancer_therapy_for_advanced_melanoma.pdf
Accepted Author Manuscript
License: Strathprints license 1.0
Download (619kB)| Preview

Abstract

Aim: Assess the real-world effectiveness of systemic anticancer therapy in advanced (unresectable or metastatic) melanoma. Methods: This was a retrospective cohort study linking routine healthcare data with systemic anticancer therapy prescriptions for patients starting immunotherapy or targeted treatments between 1 November 2010 and 31 December 2017 in the west of Scotland. Results: Among 362 patients identified, median overall survival varied between 18.5 months (95% CI: 14.4-not estimable) for ipilimumab/nivolumab combination and 5.6 months (95% CI: 4.5-7.3) for dabrafenib, but there were differences in the characteristics of each regimen cohort. Raised lactate dehydrogenase levels and Eastern Cooperative Oncology Group performance status =2 negatively impacted overall survival. Conclusion: The patients had a shorter median overall survival than those in pivotal trials. This was expected, given that this real-world cohort included patients with poorer prognostic indicators, typically excluded from trials.

CORE (COnnecting REpositories)